| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
DHS-I targets calcium-activated potassium (maxi-K/BKCa) channels (KCa1.1).
|
|---|---|
| ln Vitro |
Dehydrosoyasaponin I acts as a potent and reversible activator of maxi-K channels. The activation of these channels leads to membrane hyperpolarization, which reduces cellular excitability. In vascular smooth muscle cells, this results in vasorelaxation. In neurons, activation of BKCa channels decreases action potential firing frequency. The compound's activity is reversible, and it exhibits specificity for the maxi-K channel subtype over other potassium channel families.
|
| ln Vivo |
Specific in vivo animal efficacy data for Dehydrosoyasaponin I as a standalone drug is not extensively documented in public resources. As a BKCa channel activator, its in vivo effects are expected to include vasodilation and reduction of blood pressure in animal models. It may also have effects on neuronal excitability and smooth muscle contractility. However, detailed studies on its pharmacokinetics and efficacy in disease models are not widely available. General pharmacology profiles are inferred from its mechanism of action.
|
| Enzyme Assay |
Binding affinity studies for Dehydrosoyasaponin I to maxi-K channels are typically conducted using electrophysiological techniques rather than classical radioligand binding. Inside-out or outside-out patch-clamp recordings are performed on HEK-293 cells or CHO cells heterologously expressing BKCa channel alpha and beta subunits (KCNMA1 + KCNMB1). Channel activation is measured as an increase in open probability (Po) and mean open time in response to DHS-I application at various concentrations (1-100 nM). Reversibility of activation is assessed upon washout.
|
| Cell Assay |
HEK-293 or CHO cells stably or transiently transfected with BKCa channel alpha subunit (KCNMA1) alone or with auxiliary beta1 (KCNMB1), beta2, beta3, or beta4 subunits are cultured. Whole-cell patch-clamp electrophysiology is performed to measure macroscopic BKCa currents. Cells are voltage-clamped at holding potentials ranging from -80 to +100 mV. Dehydrosoyasaponin I is applied via bath perfusion at concentrations of 0.1-100 nM. Current amplitudes before, during, and after compound application are recorded and normalized to control. Data analysis includes calculation of fold-activation and EC50 determination.
|
| Animal Protocol |
In vivo animal experiments specifically using Dehydrosoyasaponin I are not well-documented in publicly available literature. For related BKCa channel activators, typical in vivo protocols involve intravenous or intraperitoneal administration to rodents (rats or mice) to assess cardiovascular effects. Blood pressure and heart rate are monitored via telemetry or tail-cuff plethysmography. Tissue samples may be collected to assess target engagement, though this is rarely done for natural product saponins in standard safety pharmacology screens.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is publicly available for Dehydrosoyasaponin I. As a triterpenoid saponin with high molecular weight (941.12), it is predicted to have poor oral bioavailability due to low membrane permeability and potential efflux by transporters (e.g., P-glycoprotein). It is soluble in polar organic solvents (DMSO, ethanol). Storage conditions: -20degC in powder form (stable for 12 months according to some suppliers). For research use, stock solutions are typically prepared in DMSO and diluted in aqueous buffers immediately before use.
|
| Toxicity/Toxicokinetics |
No standard toxicology data is available. As a natural product saponin, saponins are generally known to cause hemolysis (red blood cell lysis) when present in the bloodstream at high concentrations. Hemolytic activity is a common class effect of many saponins and glycosides due to membrane disruption. However, specific hemolytic or other toxicity data for Dehydrosoyasaponin I is not available in public databases. Standard laboratory safety precautions should be followed. The compound is strictly for research use only, not for human or veterinary use.
|
| References | |
| Additional Infomation |
Dehydrosoyasaponin I is a triterpenoid saponin. It has been reported to exist in *Hedysarum polybotrys*, *Impatiens siculifer*, and other organisms with relevant data. It has also been reported to originate from *Wistaria brachybotrys*; its structure is described in the first reference.
Dehydrosoyasaponin I is a research chemical used as a maxi-K (BKCa) channel activator for studying calcium-activated potassium channels in membrane physiology. It is a natural product isolated from soybeans and is also known as Soyasaponin Be. It is used as a pharmacological tool compound for electrophysiology studies exploring roles of BKCa channels in smooth muscle, neurons, and endocrine cells. It has not entered clinical trials and is not approved as a therapeutic agent. It is strictly for laboratory research use only. |
| Molecular Formula |
C48H76O18
|
|---|---|
| Molecular Weight |
941.11
|
| Exact Mass |
940.503
|
| CAS # |
117210-14-7
|
| PubChem CID |
15608214
|
| Appearance |
Solid powder
|
| Melting Point |
272 - 280 °C
|
| Vapour Pressure |
0mmHg at 25°C
|
| Source |
Originated from plants: Leguminosae Medicago sativa L.
|
| LogP |
0.913
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
66
|
| Complexity |
1860
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3O[C@H]4CC[C@]5([C@H]([C@@]4(C)CO)CC[C@@]6([C@@H]5CC=C7[C@]6(CC[C@@]8([C@H]7CC(CC8=O)(C)C)C)C)C)C)C(=O)O)O)O)CO)O)O)O)O)O
|
| InChi Key |
CROUPKILZUPLQA-ITVSDQETSA-N
|
| InChi Code |
InChI=1S/C48H76O18/c1-21-29(52)31(54)35(58)40(61-21)65-37-32(55)30(53)24(19-49)62-41(37)66-38-34(57)33(56)36(39(59)60)64-42(38)63-28-12-13-45(5)25(46(28,6)20-50)11-14-48(8)26(45)10-9-22-23-17-43(2,3)18-27(51)44(23,4)15-16-47(22,48)7/h9,21,23-26,28-38,40-42,49-50,52-58H,10-20H2,1-8H3,(H,59,60)/t21-,23-,24+,25+,26+,28-,29-,30-,31+,32-,33-,34-,35+,36-,37+,38+,40-,41-,42+,44+,45-,46+,47+,48+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8aR,12aS,14aR,14bR)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-9-oxo-2,3,4a,5,6,7,8,10,12,12a,14,14a-dodecahydro-1H-picen-3-yl]oxy]-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid
|
| Synonyms |
Soyasaponin Be;DHS-I
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0626 mL | 5.3129 mL | 10.6258 mL | |
| 5 mM | 0.2125 mL | 1.0626 mL | 2.1252 mL | |
| 10 mM | 0.1063 mL | 0.5313 mL | 1.0626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
